Is Return To Profit Altering The Investment Case For Legend Biotech (LEGN)?

详细摘要
Legend Biotech reported third quarter 2026 revenue of US$359.5 million and net income of US$51.7 million, compared with revenue of US$272.4 million and a net loss of US$39.6 million in the same period a year earlier.
Compare Legend Biotech's shift to profitability with other potential breakout stories by scanning our hand picked list of 19 high quality undiscovered gems in similar high opportunity corners of the market.
To own Legend Biotech, you need to be comfortable with a story that rests heavily on CARVYKTI and the idea that this therapy can support a full cell therapy platform. The move to quarterly profitability gives you evidence that the current product mix and cost base can support positive earnings. The key near term catalyst remains CARVYKTI expansion into earlier treatment lines and more geographies.
The biggest risk is still concentration. Any future hit to CARVYKTI use, pricing or safety could quickly undo the profit inflection. Higher and more complex tax expense, already visible in the analyst consensus Narrative on Simply Wall St, could also cap how much of the operational upside shows up in net income.
Among recent developments, the November 2026 earnings release matters most for that thesis. Revenue of US$359.5 million for the quarter and US$1,052.1 million for the first nine months, paired with net income of US$51.7 million and US$30.6 million respectively, shows Legend Biotech operating at a scale where cost discipline and manufacturing efficiency really start to matter.
Basic earnings per share from continuing operations of US$0.26 for the quarter and US$0.16 year to date give you a cleaner line of sight on how incremental CARVYKTI volume, tax expense in the high 20% range and any new in vivo programs might affect per share results. For the near term, execution on manufacturing, site onboarding and safety monitoring remains the practical catalyst to watch.
Legend Biotech's analyst narrative points to forecast revenue of US$2.1b and projected earnings of US$390.1 million by 2029. This implies revenue growth of 18.5% per year and an earnings swing of about US$481.6 million from current earnings of a US$91.5 million loss.
Uncover why Legend Biotech's fair value…
For…
文章开头,摘自Yahoo Finance。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (finance.yahoo.com)




